Clinical Trial Update: Nicotinic Cholinergic Modulation as a Novel Treatment Strategy for Aggression Associated With Autism [Phase 1]

View source ↗

Summary

Phase 1 clinical trial exploring nicotinic cholinergic modulation as a treatment strategy for aggression in autism spectrum disorder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aggression
• Autism Spectrum Disorder
• Irritability

Snippet

Sponsor: Yale University | Conditions: Autism Spectrum Disorder, Aggression | Phase 1 | Status: COMPLETED | Results posted: 2019-03-14